PAP
SABS icon

Persistent Asset Partners’s SAB Biotherapeutics SABS Stock Holding History

Persistent Asset Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.1K Sell
25,400
-44,332
-64% -$165K 0.03% 295
2026
Q1 		$267K Buy
69,732
+49,942
+252% +$199K 0.1% 163
2025
Q4 		$74K Buy
+19,790
New +$65.1K 0.03% 280

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Persistent Asset Partners's SABS Position: Q2 2026 in Review

Persistent Asset Partners reduced its SAB Biotherapeutics (SABS) stake by 64% in Q2 2026, selling an estimated $165K and leaving 25,400 shares worth $99.1K. The position accounts for 0.03% of the portfolio, ranked #295.

Persistent Asset Partners first reported a position in SABS in Q4 2025 and has held it in 3 quarters since. The position peaked at $267K in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Persistent Asset Partners held 25,400 shares of SAB Biotherapeutics worth $99.1K as of Q2 2026.
  • Persistent Asset Partners sold 44,332 SAB Biotherapeutics shares in Q2 2026, an estimated $165K.
  • SAB Biotherapeutics made up 0.03% of Persistent Asset Partners's portfolio in Q2 2026, its #295 holding.
  • Persistent Asset Partners first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's SAB Biotherapeutics position peaked at $267K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.